文献速递类风湿关节炎

sarilumab联合csDMARDs治疗类风湿关节炎的系统综述与网络荟萃分析

Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
PubMed 文献 · RMD Open · 2019-02-18

该研究通过系统文献综述和网络荟萃分析,比较了皮下注射sarilumab 200mg或150mg每两周一次联合csDMARDs与其他靶向DMARDs联合csDMARDs及安慰剂联合csDMARDs在csDMARD-IR或TNFi-IR类风湿关节炎患者中的疗效与安全性,共纳入53项试验。结果显示,在csDMARD-IR患者中,sarilumab联合csDMARDs在所有结局上优于安慰剂,与大多数靶向DMARDs无显著差异;在TNFi-IR患者中,sarilumab 200mg在部分结局上优于某些药物,安全性相似。

要点

  • csDMARD-IR患者中,sarilumab 200mg和150mg联合csDMARDs在所有疗效结局上优于安慰剂。
  • sarilumab 200mg在24周mTSS上优于巴瑞替尼2mg、托法替布和certolizumab。
  • TNFi-IR患者中,sarilumab 200mg在DAS28<2.6上优于阿巴西普、戈利木单抗、托珠单抗4mg/kg和利妥昔单抗。

核心结论

  • 在csDMARD-IR和TNFi-IR(较小网络)患者中,sarilumab联合csDMARDs相比安慰剂联合csDMARDs具有更优疗效和相似安全性。
  • sarilumab联合csDMARDs与其他靶向DMARDs联合csDMARDs相比,疗效和安全性至少相似。

研究设计与样本

  • 系统文献综述和网络荟萃分析,纳入53项试验,评估24周疗效和安全性结局。
  • 研究对象为对csDMARDs或TNFi应答不足的类风湿关节炎患者。

主要发现

  • csDMARD-IR:sarilumab 200mg和150mg联合csDMARDs在所有结局上优于安慰剂联合csDMARDs。
  • csDMARD-IR:sarilumab 200mg与大多数靶向DMARDs无统计学显著差异,但在24周mTSS上优于巴瑞替尼2mg、托法替布和certolizumab。
  • csDMARD-IR:sarilumab 150mg与所有靶向DMARDs相似。
  • TNFi-IR:sarilumab 200mg在ACR20/50/70上与阿巴西普、戈利木单抗、托珠单抗4mg和8mg/kg静脉及利妥昔单抗相似,在ACR50和DAS28<2.6上优于巴瑞替尼2mg,在DAS28<2.6上优于阿巴西普、戈利木单抗、托珠单抗4mg/kg静脉及利妥昔单抗。
  • TNFi-IR:sarilumab 150mg与靶向DMARDs相似,但在DAS28<2.6上优于巴瑞替尼2mg和利妥昔单抗,在ACR20和DAS28<2.6上劣于托珠单抗8mg。

关键数值与推荐

  • 评估结局包括HAQ-DI、mTSS(含52周)、ACR20/50/70、DAS28<2.6、严重感染/严重不良事件(含52周)。
  • sarilumab 200mg和150mg每两周一次皮下注射联合csDMARDs。

临床怎么用

  • 对于csDMARD-IR的类风湿关节炎患者,sarilumab联合csDMARDs可作为有效的治疗选择。
  • 对于TNFi-IR患者,sarilumab联合csDMARDs的疗效与许多其他靶向DMARDs相似,安全性相当。

局限性

  • TNFi-IR网络较小。
  • 未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare efficacy and safety of subcutaneous sarilumab 200 mg and 150 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs (+csDMARDs) versus other targeted DMARDs+csDMARDs and placebo+csDMARDs, in inadequate responders to csDMARDs (csDMARD-IR) or tumour necrosis factor α inhibitors (TNFi-IR). METHODS: Systematic literature review and network meta-analyses (NMA) conducted on 24 week efficacy and safety outcomes: Health Assessment Questionnaire Disability Index, modified total sharp score (mTSS, including 52 weeks), American College of Rheumatology (ACR) 20/50/70, European League Against Rheumatism Disease Activity Score 28-joint count erythrocyte sedimentation rate (DAS28)<2.6; serious infections/serious adverse events (including 52 weeks). RESULTS: 53 trials were selected for NMA. csDMARD-IR: Sarilumab 200 mg+csDMARDs and 150 mg+csDMARDs were superior versus placebo+csDMARDs on all outcomes. Against most targeted DMARDs, sarilumab 200 mg showed no statistically significant differences, except superiority to baricitinib 2 mg, tofacitinib and certolizumab on 24 week mTSS. Sarilumab 150 mg was similar to all targeted DMARDs. TNFi-IR: Sarilumab 200 mg was similar to abatacept, golimumab, tocilizumab 4 mg and 8 mg/kg intravenously and rituximab on ACR20/50/70, superior to baricitinib 2 mg on ACR50 and DAS28<2.6 and to abatacept, golimumab, tocilizumab 4 mg/kg intravenously and rituximab on DAS28<2.6. Sarilumab 150 mg was similar to targeted DMARDs but superior to baricitinib 2 mg and rituximab on DAS28<2.6 and inferior to tocilizumab 8 mg on ACR20 and DAS28<2.6. Serious adverse events, including serious infections, appeared similar for sarilumab versus comparators. CONCLUSIONS: Results suggest that in csDMARD-IR and TNFi-IR (a smaller network), sarilumab+csDMARD had superior efficacy and similar safety versus placebo+csDMARDs and at least similar efficacy and safety versus other targeted DMARDs+csDMARDs.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Choy E, Freemantle N, Proudfoot C, et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019. PMID: 30886733. doi:10.1136/rmdopen-2018-000798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。